ArticleDiscover oncology2025
A 10-year bibliometric analysis in the field of osteosarcoma treatment from 2014 to 2023.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Circular RNAs in osteosarcoma: mechanistic insights, autophagy regulation, and potential therapeutic strategies.Cancer cell international · 2026Review
- Commentary: Bibliometric analysis of targeted immunotherapy for osteosarcoma-current knowledge, hotspots and future perspectives.Frontiers in immunology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis paper aims to explore the research hot spot and development trend in osteosarcoma treatment using a bibliometric method based upon Web of Science Core Collection (WoSCC) platform over the last decade.
methodsThe literature related to osteosarcoma and cure which were published from January 2014 to December 2023 were retrieved from the database of WoSCC and made an overall analysis for the papers published including number of articles, distribution of countries and institutions, author information, and keywords, with the CiteSpace 6.2.R5.
resultsA total of 3131 papers were retrieved, including 2601 articles and 530 reviews, and the number of papers published has been increasing year by year in the last decade. There were 415 countries and 10,719 research institutions participating into the study. China's output of literature was the highest relying on its 1490 papers published, followed by The United States (548 papers). Shanghai Jiaotong university had the largest number of papers published (121 papers) and Central South University ranked second (82 papers). A total of 16,816 authors participated in the study. The number of the paper published by Massimo Serra of the Rizzoli Orthopaedics Institute was the largest (27 papers), followed by Dominique Heymann of the University of Sheffield (20 papers). The visualization analysis of keywords by CiteSpace software showed that the drug resistance, drug delivery, tumor tissue engineering and gene expression have become hotspots in the field of osteosarcoma treatment. Drug resistance significantly limits the effectiveness of current cancer treatments. Drug delivery technology not only enhances the targeting and efficacy of drugs but also helps to overcome drug resistance. The stem cells, targeted therapy, and tumor microenvironment represent the new research trends. In particular, the tumor microenvironment plays a key role in tumor development, progression, and drug resistance, and it offers numerous potential therapeutic targets.
conclusionOur investigation has identified key research foci and hotspots in osteosarcoma treatment, including drug resistance mechanisms, innovations in drug delivery technology, stem cell development, tumor microenvironment analysis, the development of novel therapies, and the clinical translation of tumor tissue engineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.